IP Library Granted Patent US 10,894,956
Granted Patent B2
US 10,894,956 · App. 15/911,624 · Granted Jan 19, 2021

Phospholipid nanogel for exoglycosidase enzyme stabilization

Inventors: Lisa Holland (Morgantown, WV); Srikanth Gattu (Morgantown, WV)
Assignee: West Virginia University
C12N9/96B81B1/006B82Y30/00C07F9/10C07F9/106C11C3/06C11C3/10C12N9/2402
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,894,956
App. No.
15/911,624
Granted
Jan 19, 2021
Kind
B2
Abstract

Described herein are phospholipid nanogels that can contain a low concentration (less than about 250 μUnits/μL) of an exoglycosidase enzyme. Also described herein are systems and devices that can contain a phospholipid nanogel that can contain a low concentration (less than about 250 μUnits/μL) of an exoglycosidase enzyme. Also described herein are methods of using the phospholipid nanogels described herein and devices and systems that can contain a phospholipid nanogel described herein.

Claims (9)

1. A phospholipid nanogel comprising:

a lipid comprising 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and 1,2-dihexanoyl-sn-glycero-3-phosphocholine (DHPC) with a ratio of DMPC to DHPC that ranges from 2.0 to 3.0, wherein the lipid is in an amount effective to produce a gel transition temperature of about 23° C., wherein the phospholipid nanogel has a fluid-like viscosity at a temperature range from 4° C. to about 23° C., and wherein the phospholipid nanogel forms a viscous gel from about 23° C. to 60° C.;

and an amount of an exoglycosidase enzyme that ranges from about 0.001 μUnits/μL of the phospholipid nanogel to about 250 μUnits/μL of the phospholipid nanogel, and

wherein the pH of the phospholipid nanogel ranges from about 4 to about 8.

2. The phospholipid nanogel of claim 1 , wherein the exoglycosidase enzyme can be selected from the group consisting of: α1-2 Fucosidase, α1-6 Fucosidase, α1-2 Mannosidase, α1-2,3 Mannosidase, α1-2,3,4,6 Fucosidase, α1-2,3,6 Mannosidase, α1-2,4,6 Fucosidase, α1-2,4,6 Fucosidase O, α1-3,4 Fucosidase, α1-3,4,6 Galactosidase, α1-3,6 Galactosidase, α1-6 Mannosidase, α2-3 Neuraminidase, α2-3 Neuraminidase S, α2-3,6 Neuraminidase, α2-3,6,8 Neuraminidase, α2-3,6,8,9 Neuraminidase, α2-3,6,8,9 Neuraminidase A, α-N-Acetylgalactosaminidase, β1-3 Galactosidase, β1-3,6 Galactosidase, β1-4,6 Galactosidase, β1-3,4 Galactosidase, β1-4 Galactosidase, β1-4 Galactosidase S, β-1-2,3,4,6-N-Acetylglucosaminidase, β-N-Acetylglucosaminidase S, β-N-Acetylhexosaminidase and any combination thereof.

3. The phospholipid nanogel of claim 1 , wherein the phospholipid nanogel further comprises a reagent selected from the group consisting of: sodium phosphate, potassium phosphate, citric acid, 2-morpholin-4-ylethanesulfonic acid, 3-(N-Morpholino)propanesulfonic acid, sodium acetate, ammonium acetate, calcium, magnesium, sodium azide, mM ethylenediaminetetraacetic acid, and any combination thereof.

4. A device comprising:

the phospholipid nanogel of claim 1 contained in a capillary or a microchannel.

5. The phospholipid nanogel of claim 1 , wherein the phospholipid nanogel is composed of 10% or more of the lipid by volume.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 2, 2022
From: WEST VIRGINIA UNIVERSITY RESEARCH CORP
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061045/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2018
From: HOLLAND, LISA; GATTU, SRIKANTH
To: WEST VIRGINIA UNIVERSITY
Reel/Frame 046583/0679 →
Continuity (2)
Provisional Application 62467072 · Mar 3, 2017
Related Publication 20180251752A1 · Sep 6, 2018